The Food and Drug Administration of the U.S. issued a warning letter last month to address the quality and safety issues regarding generic drugs. An Indian, Chinese, and the U.S. drugmakers are the subjects of the accusation. The FDA has placed the firms "On Alert" considering the observations that betided during the inspection, in April and May.
The FDA's warning letter to the Chinese drugmaker Xi’an Livingbond an accusation for not having a sufficient quality control unit and a high tech monitoring program for its manufacturing operations. The Indian homeopathic firm, Rxhomeo Private Limited, was issued a warning letter for not being able to maintain the test that affects purity, strength, and quality in its products. Meanwhile, the FDA also warned the two U.S based company, Kratom NC and Cali Botanicals, for marketing unapproved new drugs and misbranded drugs based on claims that their kratom-based products can treat opioid addiction.